- Erythroid maturation agents, which promote red blood cell maturation, are becoming increasingly important in the treatment of hematologic disorders such as beta-thalassemia and myelodysplastic syndromes (MDS), due to their ability to reduce transfusion dependence and improve patient quality of life
- The rising demand for erythroid maturation agents is primarily driven by growing prevalence of chronic anemia-related diseases, expanding clinical approvals, and increased awareness and access to targeted biologic therapies
- North America dominated the erythroid maturation agent market with the largest revenue share of 42.1% in 2024, supported by a high number of patients with rare blood disorders, rapid adoption of biologics, favorable reimbursement frameworks, and early regulatory approval and uptake of agents such as Reblozyl particularly in the U.S.
- Asia-Pacific is expected to be the fastest growing region in the erythroid maturation agent market during the forecast period due to a large undiagnosed patient population, rising healthcare investment, and greater inclusion of erythroid maturation agents in clinical guidelines across developing countries
- Reblozyl segment dominated the erythroid maturation agent market with a market share of 89.8% in 2024, attributed to its dual indication for beta-thalassemia and MDS, proven clinical efficacy, and early market entry as the first approved agent in this category
